Health technology assessment (HTA) supports evidence-informed health policy and sustainable universal health coverage. This study reviewed HITAP’s HTA capacity-strengthening activities from 2010 to mid-2025 and interviewed HTA decision-makers from seven countries. A total of 278 activities across 25

EXECUTIVE SUMMARY  The Health Intervention and Technology Assessment Program Foundation (HITAP), Thailand, undertook a mission to Colombo, Sri Lanka, supported by the World Bank Group. The mission aimed to support national efforts to strengthen capacity on health priority setting and institutiona

Executive Summary The use of Precision Medicine (PM) is increasing across Asia at a pace that outstrips the capacity of existing Health Technology Assessment (HTA) and reimbursement systems to respond. The “Workshop on Paying for Precision Medicine Sustainably in Asia: Reimbursement Barriers, Ena

The Standard Cost List for Health Technology Assessment in Thailand provides the foundational cost data for Health Technology Assessment (HTA) and economic evaluation studies. It supplies robust, context-specific cost data to inform evidence-based policy, specifically for developing and revising benefit packages under Thailand’s Universal Coverag

Abstract Understanding the financial and health consequences if economic evaluation assumptions prove incorrect is essential for managing the risk associated with benefit package decisions, particularly in resource-constrained and overburdened healthcare systems. Yet these are also the settings t

Abstract Health technology faces rising costs, system complexities, and gaps between development and coverage policies, limiting translation into practice. Traditional health technology assessment (HTA) evaluates technologies at late stages, providing little support if a technology fails to secur

The research and development of new medicines is a lengthy and sequential process that spans more than a decade, culminating in regulatory approval based on evidence of quality, safety, and efficacy from clinical trial data. In Thailand, it takes nearly an additional decade for new medicines to be included in the Thailand National List of Essential

Non-communicable diseases (NCDs) are often called “silent killers”, but there is nothing silent about their impact. They remain one of the hardest public health battles to win. According to the World Health Organisation (WHO), they cause 43 million deaths worldwide and account for 75% of non-pandemi

Background & RationaleNon-communicable diseases (NCDs) are the leading cause of death worldwide, responsible for 43 million deaths annually and accounting for 75% of all non-pandemic-related mortality globally [1]. Cardiovascular disease, diabetes, cancer, and chronic respiratory conditions drive this burden, yet most health systems remain orie

Antimicrobial resistance (AMR) is one of the most pressing public health challenges worldwide. It occurs when antimicrobials—such as antibiotics, antifungals, antivirals, and antiparasitics—become ineffective against microorganisms like bacteria, fungi, viruses, and parasites. This resistance can le